| Not Yet Recruiting | A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Opt NCT07012044 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leuk NCT06871410 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia NCT07263906 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT07025564 | City of Hope Medical Center | Phase 1 |
| Recruiting | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients Wi NCT06484062 | National Cancer Institute (NCI) | Phase 1 |
| Suspended | A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06763341 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Pati NCT06572631 | City of Hope Medical Center | Phase 1 |
| Suspended | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refr NCT06454409 | City of Hope Medical Center | Phase 1 |
| Recruiting | CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) NCT06834282 | CERo Therapeutics Holdings, Inc. | Phase 1 |
| Recruiting | TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes W NCT03816319 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML NCT06561152 | Stanford University | Phase 1 / Phase 2 |
| Recruiting | Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia NCT07014449 | Hangzhou Weben Pharma Co., Ltd | Phase 1 |
| Recruiting | Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML NCT06741722 | Beijing 302 Hospital | Phase 2 |
| Recruiting | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia NCT06399640 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS NCT06536959 | Beijing 302 Hospital | Phase 2 |
| Recruiting | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrom NCT06501196 | BlossomHill Therapeutics | Phase 1 |
| Not Yet Recruiting | Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML NCT06385808 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Recruiting | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relap NCT06177067 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML NCT06418776 | National Research Center for Hematology, Russia | Phase 3 |
| Recruiting | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and NCT06222580 | Uma Borate | Phase 1 |
| Recruiting | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia NCT05672147 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leu NCT05146739 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Tazemetostat and Palbociclib With CPX-351for R/R AML NCT05627232 | Thomas Jefferson University | Phase 1 |
| Recruiting | A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia NCT06017258 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation NCT04203316 | Children's Oncology Group | Phase 2 |
| Withdrawn | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Tr NCT05320380 | Children's Oncology Group | Phase 1 / Phase 2 |
| Withdrawn | Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or NCT04354025 | Washington University School of Medicine | Phase 2 |
| Recruiting | 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute NCT05263284 | City of Hope Medical Center | Phase 1 |
| Recruiting | Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05597306 | Terrence J Bradley, MD | Phase 1 |
| Active Not Recruiting | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT05441514 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Le NCT05396859 | OHSU Knight Cancer Institute | Phase 1 |
| Terminated | A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Rel NCT05028751 | Kronos Bio | Phase 1 / Phase 2 |
| Withdrawn | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML a NCT05456269 | Race Oncology Ltd | Phase 1 |
| Active Not Recruiting | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Prev NCT05222984 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS NCT04893915 | Washington University School of Medicine | Phase 2 |
| Unknown | Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloi NCT05362942 | Beijing 302 Hospital | Phase 2 |
| Recruiting | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms NCT04797767 | University of Washington | Phase 1 / Phase 2 |
| Terminated | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplast NCT04874194 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With NCT04898894 | St. Jude Children's Research Hospital | Phase 1 |
| Unknown | Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS NCT04749355 | BioSight Ltd. | Phase 2 |
| Active Not Recruiting | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute M NCT04975919 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT04956042 | CicloMed LLC | Phase 1 / Phase 2 |
| Recruiting | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutate NCT05010122 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies NCT04891757 | Foghorn Therapeutics Inc. | Phase 1 |
| Withdrawn | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relap NCT04774393 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatr NCT04915612 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia NCT04526795 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia NCT04835519 | Beijing Boren Hospital | Phase 1 / Phase 2 |
| Terminated | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acu NCT04752163 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia NCT04746235 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction NCT04049539 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS NCT04668885 | Case Comprehensive Cancer Center | Phase 2 |
| Unknown | Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. NCT04904237 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Recruiting | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic S NCT04493164 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid NCT04250051 | Northwestern University | Phase 1 |
| Recruiting | CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatmen NCT04375631 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced M NCT04146038 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid NCT04207190 | Roswell Park Cancer Institute | Phase 1 |
| Withdrawn | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Fron NCT04493099 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Synd NCT03953898 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia NCT04435691 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or NCT04487106 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML NCT04220684 | Sumithira Vasu | Phase 1 |
| Unknown | Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Hae NCT04470947 | Medical University of Vienna | — |
| Recruiting | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia an NCT04128748 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML NCT04424147 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Active Not Recruiting | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leuk NCT04188405 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT04196010 | University of Washington | Phase 1 |
| Completed | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia NCT04562792 | Children's Mercy Hospital Kansas City | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytar NCT03983824 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or My NCT03969446 | City of Hope Medical Center | Phase 1 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid NCT03701295 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia NCT04158739 | Children's Oncology Group | Phase 1 |
| Recruiting | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute My NCT04140487 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation NCT03881735 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Re NCT04047641 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Ac NCT04000698 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 |
| Withdrawn | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Le NCT04013880 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or NCT03874052 | Jennifer Saultz | Phase 1 |
| Recruiting | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelody NCT03772925 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute NCT03745352 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refract NCT03813147 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia NCT03752138 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurren NCT03634228 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML NCT05456048 | Nanfang Hospital, Southern Medical University | — |
| Active Not Recruiting | Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute NCT03513484 | Northwestern University | Phase 1 |
| Active Not Recruiting | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or NCT03672539 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leuk NCT03661307 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractor NCT03629171 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Re NCT03600155 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia NCT03557970 | OHSU Knight Cancer Institute | Phase 2 |
| Active Not Recruiting | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Diso NCT03289910 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 G NCT03683433 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acu NCT03519984 | University of Southern California | Phase 1 |
| Recruiting | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malig NCT03471260 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients W NCT03041688 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia NCT03035422 | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | N/A |
| Completed | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute NCT03390296 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplast NCT03067571 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia NCT03291353 | Michael Boyiadzis | EARLY_Phase 1 |
| Recruiting | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory A NCT03214562 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute M NCT02890329 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia NCT03009240 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia U NCT03247088 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leuk NCT03132454 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820 | Mayo Clinic | Phase 1 |
| Completed | STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is NCT03063944 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Terminated | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT02953561 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS NCT02921061 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid NCT02882321 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grad NCT02756572 | University of Washington | Phase 2 |
| Completed | Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leu NCT02649764 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT02159495 | City of Hope Medical Center | Phase 1 |
| Recruiting | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome NCT02392572 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory NCT02551718 | University of Washington | N/A |
| Completed | 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02509546 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Terminated | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies NCT02381548 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML NCT02109627 | C. Babis Andreadis | Phase 1 |
| Terminated | Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT02399917 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Di NCT02397720 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferati NCT02257138 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Ac NCT02070458 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01787474 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk NCT02115295 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leuk NCT01892371 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01961765 | Massachusetts General Hospital | Phase 1 |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Terminated | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelog NCT01620216 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Re NCT01249430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01130506 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Maligna NCT00426205 | Dana-Farber Cancer Institute | N/A |